anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cardioembolic stroke is one of the most devastating complications of nonischemic dilated cardiomyopathy (NIDCM). However, in clinical trials of primary prevention, the benefits of anticoagulation are hampered by the risk of bleeding. Indices of cardiac blood stasis may account for the risk of stroke and be useful to individualize primary prevention treatments. We performed a cross-sectional study in patients with NIDCM and no history of atrial fibrillation (AF) from two sources: 1) a prospective enrollment of unselected patients with left ventricular (LV) ejection fraction <45% and 2) a retrospective identification of patients with a history of previous cardioembolic neurological event. The primary end point integrated a history of ischemic stroke or the presence intraventricular thrombus, or a silent brain infarction (SBI) by imaging. From echocardiography, we calculated blood flow inside the LV, its residence time (TR) maps, and its derived stasis indices. Of the 89 recruited patients, 18 showed a positive end point, 9 had a history of stroke or transient ischemic attack (TIA) and 9 were diagnosed with SBIs in the brain imaging. Averaged TR, [Formula: see text] performed well to identify the primary end point [AUC (95% CI) = 0.75 (0.61-0.89), P = 0.001]. When accounting only for identifying a history of stroke or TIA, AUC for [Formula: see text] was 0.92 (0.85-1.00) with odds ratio = 7.2 (2.3-22.3) per cycle, P < 0.001. These results suggest that in patients with NIDCM in sinus rhythm, stasis imaging derived from echocardiography may account for the burden of stroke.NEW & NOTEWORTHY Patients with nonischemic dilated cardiomyopathy (NIDCM) are at higher risk of stroke than their age-matched population. However, the risk of bleeding neutralizes the benefit of preventive oral anticoagulation. In this work, we show that in patients in sinus rhythm, the burden of stroke is related to intraventricular stasis metrics derived from echocardiography. Therefore, stasis metrics may be useful to personalize primary prevention anticoagulation in these patients.
The electrocardiogram (ECG) is a fundamental and widely used tool for diagnosing cardiovascular diseases. It involves recording cardiac electrical signals using electrodes, which illustrate the functioning of cardiac muscles during contraction and relaxation phases. ECG is instrumental in identifying abnormal cardiac activity, heart attacks, and various cardiac conditions. Arrhythmia detection, a critical aspect of ECG analysis, entails accurately classifying heartbeats. However, ECG signal analysis demands a high level of expertise, introducing the possibility of human errors in interpretation. Hence, there is a clear need for robust automated detection techniques. Recently, numerous methods have emerged for arrhythmia detection from ECG signals. In our research, we developed a novel one-dimensional deep neural network technique called linear deep convolutional neural network (LDCNN) to identify arrhythmias from ECG signals. We compare our suggested method with several state-of-the-art algorithms for arrhythmia detection. We evaluate our methodology using benchmark datasets, including the PTB Diagnostic ECG and MIT-BIH Arrhythmia databases. Our proposed method achieves high accuracy rates of 99.24% on the PTB Diagnostic ECG dataset and 99.38% on the MIT-BIH Arrhythmia dataset.
Hepatic fibrosis is a common chronic liver disease, and its severe progression can culminate in cirrhosis and hepatocellular carcinoma (HCC). Precise diagnosis and staging of hepatic fibrosis are essential to prevent liver cirrhosis and HCC. Simultaneous detection of multiplex collagen biomarkers within liver tissue is crucial for staging hepatic fibrosis. We herein for the first time constructed multiplex collagen fingerprinting for the staging of hepatic fibrosis using high-precision fluorescence-guided surface-enhanced Raman scattering (SERS) imaging. SERS/fluorescent probes, collectively referred to as SF, comprising silver nanoparticles (Ag NPs), Raman reporters, and FAM-labeled collagen targeting peptides. These probes exhibit exceptional aqueous dispersion and stability, attributed to the increased number of Asp residues in CTP. Meanwhile, SF probes, namely SF-I, SF-IV, and SF-D have demonstrated specific targeting of type I, type IV, and denatured collagen, respectively, within hepatic fibrotic tissues. The results from fluorescence-guided SERS imaging underscore the method's capacity for typing, localization, and quantification of collagen, thus providing novel insights into collagen's role in the development of hepatic fibrosis. The collagen fingerprinting strategy offers a potent toolkit for the multifaceted profiling of collagen superfamilies, holding significant implications for the precise staging of hepatic fibrosis.
This was a multi-center, open-label, phase Ib/II study. The aim of the phase Ib part was to estimate the MTD(s) and/or identify the recommended phase II dose(s) (RP2Ds) for the combination of BYL719 and AMG 479 (ganitumab), followed by the phase II part to assess the clinical efficacy and to further assess the safety of the combination in selected patient populations. The dose escalation part of the study were to be guided by a Bayesian Logistic Regression Model (BLRM).

Once MTD/RP2D had been determined, patients were to be enrolled in two Phase II arms. Patients with PIK3CA mutated or amplified hormone receptor positive breast carcinoma were to be enrolled in Arm 1; patients with PIK3CA mutated or amplified ovarian carcinoma were to be enrolled in Arm 2. Patients were to be treated until progression of disease, unacceptable toxicity develops, or withdrawal of informed consent, whichever occurred first. All patients were to be followed up. At a minimum, patients must have completed the safety follow-up assessments 30 days after the last dose of the study treatment.
The invention describes methods and agents for improving cosmetic appeara nce, for promoting, improving or restoring health of cells and tissues, pref erably skin, and more preferably, for restoring aged or damaged skin to a he althy appearance. This invention relates to the use of cells and cellular ex tracts in rejuvenation and healing technologies thereby improving healing an d regeneration of all bodily tissues and organs. The present invention relat es to compositions and methods of managing, preventing, and treating scars. The invention also relates to prevention of deterioration, damage and malfun ction of cells and tissues, and to promote, improve or exceed cellular funct ion in order to promote, improve and exceed appearance, vitality and health. In some embodiments, the invention relates to compositions of cells, eggs, cell extracts, egg extracts, and extract components such as purified nucleic acids, polypeptides, lipids, carbohydrates or other natural products. Said components can also be synthesized. In other embodiments, the cells are diff erentiable cells preferably stem cells or eggs. In some embodiments, composi tions are used in a method that comprises application of compositions to tis sues, including skin and/or wounds after removal of tissue surface layers. I n other embodiments, the invention relates to methods of dedifferentiation o f cells and/or dedifferentiation followed by differentiation. In other embod iments, the invention relates to managing, preventing, and treating skin dis eases.
Type 2 diabetes mellitus (T2DM) is a chronic progressive disease that affects more than 400 million people worldwide. Besides adapting their lifestyle, a large majority of diabetic patients needs pharmacotherapy to achieve adequate glycaemic control. Additional pharmacotherapy is usually needed for the treatment of concomitant diseases and risk factors. This can result in polytherapy which puts patients et risk of adverse drug reactions (ADRs). There are a few studies evaluating ADRs in diabetics. A prospective observation study reported ADRs in 11.8% of diabetic patients in tertiary care hospital. Many patients experience ADRs soon after hospital discharge which can be attributed to the changes in the pharmacotherapy during hospitalization. These ADRs can result in early readmission and emergency department (ED) visits. In an Italian study, ADRs were reported in 73.8% of patients taking oral antidiabetics drugs within one month of study enrollment. It is estimated that between 11-38% of ambulatory ADRs are preventable. Medication adherence plays an important role in the treatment of T2DM because it clearly improves glycaemic control and clinical outcomes and lowers medical costs. Adherence rates to DM medications vary from 31% to 87% in retrospective studies and 53% to 98% in prospective studies. It is affected by many factors such as age, race, health beliefs, medication cost, co-pays, etc. Adherence is lower in the case of ADRs, when medications are taken more than twice daily, with concomitant depression and skepticism about the importance of medication. In recent years, 30-day readmission rate has been emphasised as a measure of healthcare quality. Diabetic patients have higher readmission rate compared to patients without DM. In the study by Ostling and al., 30-day readmission rate for patients with DM was 26%. Many readmissions are drug-related and can be caused by ADRs and non-adherence. These readmissions are potentially preventable. It is estimated that between 40%-57.1% of readmissions caused by ADRs and all readmissions caused by non-adherence are preventable. Education and counseling of diabetic patients has been shown to improve medication adherence and clinical outcomes. Studies that included medical patients revealed that education can significantly reduce risk of ADRs after hospital discharge. Pharmacotherapeutic education is a part of comprehensive education of diabetics that is focused on a proper use of medications, prevention and early detection of ADRs. The aim of this study was to evaluate the impact of pharmacotherapeutic education on 30-day post discharge medication adherence and adverse outcomes (ADRs, readmissions, ED visits and death) in diabetic patients.
PROBLEM TO BE SOLVED: To obtain a composition, capable of sufficiently manifesting efficacies essentially possessed by an active oxygen scavenger and useful for a cosmetic and a medicine, etc., for external use excellent in preventing effects on skin aging and reducing effects on skin roughening by using the active oxygen scavenger with a specific glycoside in combination. SOLUTION: This composition is obtained by formulating a lignan glycoside with an active oxygen scavenger in combination. A compound represented by formula I [R is a glycosyl composed of one to four saccharides, which are one or more selected from glucose, galactose and fructose; (n) is 0 or 1], especially a compound represented by formula II (Glc is the glycosyl) or formula III or IV is preferred as the lignan glycoside. A superoxide dismutase, a catalase, mannitol, hydroquinone, catechin, gallic acid, etc., are cited as the active oxygen scavenger. The amount of the formulated lignan glycoside is 0.001-5 wt.% in the case of, e.g. the compound represented by formula I to IV and that of the active oxygen scavenger is 0.0001-5 wt.%.
A dynamic assessment of fluid responsiveness using the Starling SV monitor will be performed at every clinical decision point for the first 72 hours of study enrollment. Examples of a clinical decision point include a mean arterial pressure (MAP) of \< 65, the decision to give additional fluid volume, and the decision to either escalate or wean vasopressors. Fluid responsiveness will be assessed using a passive leg raise (PLR) to guide corresponding treatment.
Pre-eclampsia and fetal growth restriction (FGR) continue to cause unacceptably high levels of morbidity and mortality, despite significant pharmaceutical and technological advances in other disease areas. The recent pandemic has also impacted obstetric care, as COVID-19 infection increases the risk of poor pregnancy outcomes. This review explores the reasons why it lacks effective drug treatments for the placental dysfunction that underlies many common obstetric conditions and describes how nanomedicines and targeted drug delivery approaches may provide the solution to the current drug drought. The ever-increasing range of biocompatible nanoparticle formulations available is now making it possible to selectively deliver drugs to uterine and placental tissues and dramatically limit fetal drug transfer. Formulations that are refractory to placental uptake offer the possibility of retaining drugs within the maternal circulation, allowing pregnant individuals to take medicines previously considered too harmful to the developing baby. Liposomes, ionizable lipid nanoparticles, polymeric nanoparticles, and adenoviral vectors have all been used to create efficacious drug delivery systems for use in pregnancy, although each approach offers distinct advantages and limitations. It is imperative that recent advances continue to be built upon and that there is an overdue investment of intellectual and financial capital in this field.
FIELD: compositions for external application. SUBSTANCE: liquid composition of oil-in-water type for topical application contains 30-50 mas.% in terms of total mass of composition at least one glycol, conforming emulsifying system and at least one active agent. The liquid composition has preferably viscosity from 3 to 10 Pa.c (3000-10000 centipoises). Viscosity is determined with the help of Brookfield viscosimeter model LVDV 11+engine No. 4, at rotation speed of 30 rpm for 30 s and at temperature 25±3 C. The composition simplifies external use of active agent and possesses adhesive ability preserving glycol properties optimal for absorption. EFFECT: improved efficiency. 15 cl, 2 ex
Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl).
The Comparison Group followed and documented their regular workout routine for 14 weeks. Once a week, a trained firefighter with current CPR and First Aid certifications met with the group to discuss questions. Participants were able to choose when to complete their workouts.
A pharmaceutical preparation of ET18-OCH3 for intravenous administration containing a lipophilic oil-in-water emulsion can be used to administer high doses of the pharmacon ET18-OCH3 without side effects. The lipophilic emulsions in the preparation contain ordinary lipophilic particles of the size of chylomicrons. The active substance and the lipophilic emulsion in the pharmaceutical preparation are usually administered intravenously at the same time. However, the oil-in-water emulsion and the active substance can also be administered separately or at intervals. For this reason, a pharmaceutical preparation is described in which the active substance ET18-OCH3 and the lipophilic emulsion exist as a combination preparation. Also described is the use of ET18-OCH3 and the lipophilic emulsion to manufacture drugs which have an antiproliferative effect and are used to suppress immunological reactions and to treat tumours, as well as to treat multiple sclerosis and autoimmune diseases.
In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2 and to 60 mg at week 3. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 60 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14.In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
ETHNOPHARMACOLOGICAL RELEVANCE: Nao-Ling-Su Capsule (NLSC) is a traditional prescription, which is composed of fifteen herbs such as epimedium, Polygala tenuifolia, and Schisandra chinensis. It has the effect of strengthening the brain, calming nerves, and protecting the kidney, which has been used clinically for many years to strengthen the brain and kidney. However, the effect of NLSC in the treatment of acute kidney injury (AKI) is still unclear.
AIM OF THE STUDY: The present study aims to elucidate the pharmacological actions of NLSC in the treatment of AKI.
MATERIALS AND METHODS: Molecular targets for NLSC and AKI were obtained from various databases, and then we built networks of interactions between proteins (PPI) by employing string databases. Additionally, we employed the DAVID database to conduct gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Molecular docking was conducted to analyze the interaction between core components and their corresponding core targets. Next, the C57BL male mice model of ischemia/reperfusion damage (IRI) was developed, and the nephridial protective effect of NLSC was evaluated. The accuracy of the expected targets was confirmed using real-time quantitative polymerase chain reaction (RT-qPCR). The renal protective effect of NLSC was assessed using an immortalized human kidney tubular (HK-2) cell culture produced by oxygen-glucose deprivation (OGD).
RESULTS: Network pharmacology analysis identified 199 common targets from NLSC and AKI. STAT3, HSP90AA1, TP53, MAPK3, JUN, JAK2, and VEGFA could serve as potential drug targets and were associated with JAK2/STAT3 signaling pathway, PI3K-Akt signaling pathway, etc. The molecular docking analysis confirmed significant docking activity between the main bioactive components and core targets, including STAT3 and KIM-1. Moreover, the AKI mice model was successfully established and NLSC pretreatment could improve renal function and alleviate renal damage. NLSC could alleviate renal inflammation and tubular cell apoptosis, and decrease the expression of STAT3 and KIM-1 in AKI mice. In vitro, both NLSC and drug-containing serum may protect HK-2 cells by inhibiting STAT3 signaling, especially STAT3-mediated apoptosis and KIM-1 expression.
CONCLUSION: NLSC could alleviate renal inflammation and apoptosis, exerting its beneficial effects by targeting the STAT3/KIM-1 pathway. NLSC is a promising candidate for AKI treatment and provides a new idea and method for the treatment of AKI.
Carrier structure imitating biological interstitial system is provided, comprising a carrier and a plurality of ligands. The carrier encloses particles of  Taiwanofungus camphoratus.  The carrier comprises first and second liposome shells. A first space is defined inside the first liposome shell. The second liposome shell encloses the first liposome shell. An external radius of the first liposome shell is smaller than an internal radius of the second liposome shell, a second space is defined between an inside of the second liposome shell and an outside of the first liposome shell. The ligands follow at least one orbit surrounding the carrier. When approaching a specific cancer cell, the ligands move towards receptors thereof and combine therewith, so that the carrier compresses; when the carrier disintegrates due to compression, the particles of  Taiwanofungus camphoratus  are released and then scatter on the receptors to destroy the cancer cell.
The invention includes methods for producing supramolecular structures using molecular recognition, and methods for controlling the size of the nanoparticles produced in order to form discrete particles with beneficial antiviral properties. The present supramolecular nanoparticles can include: combinatorial derivatized heme-porphyrins from the group of benzimidazolated heme-porphyrins, which are obtained by a first combinatorial synthesis; combinatorial derivatized dipyridamoles obtained by a second combinatorial synthesis; basic amino acid polypeptides obtained by a third combinatorial synthesis, or combinations thereof. The supramolecular nanoparticles are dynamic self-organizing soluble nanostructures that have a plurality of binding components, organic cores and terminating components. The binding components include combinatorial derivatized heme-porphyrins with binding regions. The organic cores include a combinatorial derivatized dipyridamole adapted for binding to the combinatorial derivatized heme-porphyrins so that the organic cores are able to form a mechanical structure for the self-organizing soluble nanostructures and inclusion complexes of a first type. The supramolecular nanoparticles contain terminating components with one terminating binding element capable of binding to the residual binding region of the binding components, thus allowing the formation of inclusion complexes of a second type.
The spinocerebellar ataxias (SCAs) are a group of dominantly inherited neurodegenerative diseases, several of which are caused by CAG expansion mutations (SCAs 1, 2, 3, 6, 7 and 12) and more broadly belong to the large family of over 40 microsatellite expansion diseases. While dysregulation of alternative splicing is a well defined driver of disease pathogenesis across several microsatellite diseases, the contribution of alternative splicing in CAG expansion SCAs is poorly understood. Furthermore, despite extensive studies on differential gene expression, there remains a gap in our understanding of presymptomatic transcriptomic drivers of disease. We sought to address these knowledge gaps through a comprehensive study of 29 publicly available RNA-sequencing datasets. We identified that dysregulation of alternative splicing is widespread across CAG expansion mouse models of SCAs 1, 3 and 7. These changes were detected presymptomatically, persisted throughout disease progression, were repeat length-dependent, and were present in brain regions implicated in SCA pathogenesis including the cerebellum, pons and medulla. Across disease progression, changes in alternative splicing occurred in genes that function in pathways and processes known to be impaired in SCAs, such as ion channels, synaptic signalling, transcriptional regulation and the cytoskeleton. We validated several key alternative splicing events with known functional consequences, including Trpc3 exon 9 and Kcnma1 exon 23b, in the Atxn1154Q/2Q mouse model. Finally, we demonstrated that alternative splicing dysregulation is responsive to therapeutic intervention in CAG expansion SCAs with Atxn1 targeting antisense oligonucleotide rescuing key splicing events. Taken together, these data demonstrate that widespread presymptomatic dysregulation of alternative splicing in CAG expansion SCAs may contribute to disease onset, early neuronal dysfunction and may represent novel biomarkers across this devastating group of neurodegenerative disorders.
Subcutaneous injection every 8 weeks based on participant's body weight. Body weight \>40 kilogram (kg): 150 milligrams (mg) per injection and body weight \<= 40 kg: 2 mg/kg per injection. For participants who did not experience sufficient symptomatic relief, an up-titration to the dose and/or more frequent doses were permitted as per protocol.